# OnCo record foundationone-mrd (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/foundationone-mrd/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "foundationone-mrd" ;
  schema:name "FoundationOne MRD"@en ;
  schema:alternateName "Pathlight"@en, "Pathlight MRD"@en, "SAGA Pathlight"@en, "FoundationOne MRD" ;
  schema:description "Foundation Medicine's blood test for breast cancer coming back, launched in May 2026; it is SAGA Diagnostics' Pathlight test, which Medicare already covered."@en ;
  schema:url <https://onco.cc/drugs/foundationone-mrd/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.foundationmedicine.com/solution/foundationone-mrd>, <https://www.foundationmedicine.com/press-release/foundationone-mrd>, <https://www.foundationmedicine.com/press-release/saga-diagnostics-mrd-platform>, <https://sagadiagnostics.com/saga-diagnostics-announces-medicare-coverage-for-pathlight-mrd-test-in-breast-cancer-across-all-subtypes/>, <https://www.natera.com/company/news/foundation-medicine-and-natera-announce-broad-clinical-launch-and-medicare-coverage-of-foundationonetracker/>, <https://doi.org/10.1158/1078-0432.CCR-24-3472>, <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58376> ;
  onco:status "emerging" ;
  onco:tag "test" ;
  onco:modality "Tumour-informed ctDNA minimal residual disease test (whole-genome design, digital PCR of up to 16 structural variants)" ;
  onco:related <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/next-personal/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:companies <https://onco.cc/companies/foundation-medicine/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> .